{"ticker": {"uuid": "4b38f0b4-52fe-4af6-be6b-232eda56775d", "symbol": "PHAT", "name": "Phathom Pharmaceuticals Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Form 4 Phathom Pharmaceuticals Inc For: 16 July By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxOd0QyTWhzZy1JenVHdkpsT3JwSlBnZ3dLRHRvOXV0WEt3bHJsdkpyNkFzVHJYV2NMYmlaVEdZVG9Fejg4eDJIeVN0UEJtRXpLb05TcTdOa2FJVXo5Z3RkemtKaDJIS1I0MGRaTmpmWHJReVVBcUFoQXJUQ0ZVVm1EeUhDY04zcXVkYjdjMmdaM0lBdXAtbGw4U3VvM2wxTlhiem1HbndsT0lrYmc?oc=5", "source_name": "Investing.com Nigeria", "published_at": "2026-07-16T21:21:39+00:00", "published_display": "16 Jul 2026 21:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phathom Pharmaceuticals (PHAT) officer surrenders 1,555 for tax withholding", "summary": "Robert Charles Breedlove, Principal Accounting Officer of Phathom Pharmaceuticals, Inc., surrendered 1,555 shares of common stock at $11.035 per share on July 14, 2026, to satisfy tax withholding obligations related to restricted stock units. This F-code disposition means shares ", "url": "https://www.stocktitan.net/sec-filings/PHAT/form-4-phathom-pharmaceuticals-inc-insider-trading-activity-b3052072f91f.html", "source_name": "Stock Titan", "published_at": "2026-07-16T20:41:21", "published_display": "16 Jul 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Phathom Pharmaceuticals Inc (PHAT) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Phathom Pharmaceuticals Inc (PHAT), detailing its current price momentum score, support and resistance levels, and indicator readings. The analysis covers various technical indicators like MACD, RSI, and moving averages, concluding wi", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-phat/technical", "source_name": "TradingKey", "published_at": "2026-07-13T21:11:57", "published_display": "13 Jul 2026 21:11", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Phathom Pharmaceuticals (PHAT) Short Interest & Short Float | Updated Jul 2026 $PHAT", "summary": "As of June 30, 2026, Phathom Pharmaceuticals (PHAT) had 11.99 million shares sold short, marking a 7.44% increase from the prior report and representing 16.59% of the public float. The short interest ratio is 11.7 days to cover, indicating strong pessimism about the stock. The ar", "url": "https://www.marketbeat.com/stocks/NASDAQ/PHAT/short-interest/", "source_name": "MarketBeat", "published_at": "2026-07-10T21:11:57", "published_display": "10 Jul 2026 21:11", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avoiding Lag: Real-Time Signals in (PHAT) Movement", "summary": "Phathom Pharmaceuticals Inc. (NASDAQ: PHAT) is showing strong near and mid-term sentiment, potentially extending to a long-term uptrend, although it is currently testing resistance. AI models suggest specific trading strategies, including a long position with a target of $12.31 a", "url": "https://news.stocktradersdaily.com/news_release/132/Avoiding_Lag:_Real-Time_Signals_in_PHAT_Movement_070926093202_1783603922.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-09T09:46:05", "published_display": "09 Jul 2026 09:46", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Phathom Pharmaceuticals, Inc. \u2013 NASDAQ:PHAT", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNVGxUczdZME5FUEt6NHJGbFp3bVRMN1RyX1Q5QVlvN3MzNmR0RGxBdXFxZ3A3V19oWl9uMU1iRHQ2LV9Mc2dYTGVOZFRiOW1SRGo0RDlaQXBkTlFhM2ZfNXFZV19QTkkzQm54UjVmMF9mVWhLUktZR0xBZTJQcWdPZHR6ZlFKQi1Vd0J6WGhQVGxmd1NYczc4MjlUbFpOOHJnSEQ2SzAzLXFuTURPOEE?oc=5", "source_name": "TradingView", "published_at": "2026-07-06T09:45:27+00:00", "published_display": "06 Jul 2026 09:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Phathom Pharmaceuticals, Inc. \u2013 NASDAQ:PHAT", "summary": "This article displays the \"Price to book forward\" metric for Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) on the TradingView platform. It provides financial data and indicates that the market was closed at the time the information was presented. The content primarily lists naviga", "url": "https://www.tradingview.com/symbols/NASDAQ-PHAT/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T09:41:36", "published_display": "06 Jul 2026 09:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Phathom Pharmaceuticals, Inc. \u2013 NASDAQ:PHAT", "summary": "This article briefly mentions the \"Price to sales forward\" metric for Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT). It appears to be a financial data point from TradingView, indicating a value change for the company. The rest of the content consists of navigation links and copyri", "url": "https://www.tradingview.com/symbols/NASDAQ-PHAT/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T08:42:41", "published_display": "06 Jul 2026 08:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PHAT - Phathom Pharmaceuticals Inc Revenue Breakdown", "summary": "This article provides a detailed financial breakdown for Phathom Pharmaceuticals Inc (PHAT), including its last closing price, market capitalization, income, sales, and various financial ratios. It also lists key performance indicators, stock ownership details, and price performa", "url": "https://finviz.com/stock?t=PHAT&ta=1&p=d&ty=rv", "source_name": "Finviz", "published_at": "2026-07-01T14:40:34", "published_display": "01 Jul 2026 14:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Discipline and Rules-Based Execution in PHAT Response", "summary": "This article analyzes Phathom Pharmaceuticals Inc. (NASDAQ: PHAT), noting conflicting sentiment and a mid-channel oscillation pattern. It highlights an exceptional risk-reward setup targeting a 29.0% gain against a 0.3% risk, with specific entry, target, and stop-loss points for ", "url": "https://news.stocktradersdaily.com/news_release/139/Discipline_and_Rules-Based_Execution_in_PHAT_Response_062826082402_1782649442.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-28T08:24:00", "published_display": "28 Jun 2026 08:24", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phathom Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:PHAT)", "summary": "This article provides financial data and analyst estimates for Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT). It covers details like current stock price, historical highs and lows, market capitalization, volatility, and upcoming earnings reports. The content also addresses frequent", "url": "https://www.tradingview.com/symbols/NASDAQ-PHAT/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T05:10:25", "published_display": "26 Jun 2026 05:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PHAT Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Phathom Pharmaceuticals, Inc. (PHAT) stock, including analyst price targets and future predictions for 2027. It details the company's recent stock performance, financial metrics like revenue and earnings, and upcoming events such as the next e", "url": "https://www.tradingview.com/symbols/NASDAQ-PHAT/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T16:10:46", "published_display": "25 Jun 2026 16:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Craig-Hallum Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating", "summary": "Craig-Hallum has reiterated its Buy rating on Phathom Pharmaceuticals (PHAT.US). This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.", "url": "https://www.moomoo.com/news/post/71987765/craig-hallum-maintains-phathom-pharmaceuticals-phatus-with-buy-rating", "source_name": "Moomoo", "published_at": "2026-06-25T13:40:46", "published_display": "25 Jun 2026 13:40", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phathom Pharmaceuticals details new Voquezna launch pace, shares track gastro health focus", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxQeFVxdWN6WUpOc09La2ZFbklSQlVfY3M0ajBDODRXalRybVJnZzUtN0VVOWtpTGZaaVZZNDg2c1VEY1dlSTZiYTZiS0FqMFQ4cUtUOHdVM1JjMVJ5Qkk5anQzSk1odHlmOGpGQ01FZ2hJQXdSZmJKU3NhZTBaYzBMWWlYaEczMks3bWdlZDY4SVowUDVGZ1JyaGZiX0M4OXo0Vkh4a2oxNlFwQk9kTmZpZU1KamZ4VHNaR2hBaDlDM3ZTYUVKSEJv?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-06-25T12:07:03+00:00", "published_display": "25 Jun 2026 12:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phathom Pharmaceuticals completes enrollment in Phase 2 EoE study", "summary": "Phathom Pharmaceuticals has announced the completion of enrollment for its Phase 2 pHalcon-EoE-201 clinical trial, which is evaluating VOQUEZNA (vonoprazan) tablets for the treatment of eosinophilic esophagitis (EoE) in adults. The study enrolled 95 patients across 41 sites in th", "url": "https://www.investing.com/news/sec-filings/phathom-pharmaceuticals-completes-enrollment-in-phase-2-eoe-study-93CH-4755433", "source_name": "Investing.com", "published_at": "2026-06-23T14:10:46", "published_display": "23 Jun 2026 14:10", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phathom Pharmaceuticals Completes Patient Enrollment for Phase 2 Trial of Voquezna", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/phathom-pharmaceuticals-completes-patient-enrollment-122645393.html", "source_name": "MT Newswires", "published_at": "2026-06-23T12:26:45+00:00", "published_display": "23 Jun 2026 12:26", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phathom Pharmaceuticals completes enrollment in Phase 2 EoE study By Investing.com", "summary": "Phathom Pharmaceuticals, Inc. has announced the completion of enrollment for its Phase 2 pHalcon-EoE-201 clinical trial, which is evaluating VOQUEZNA (vonoprazan) tablets for the treatment of eosinophilic esophagitis (EoE) in adults. The trial enrolled 95 patients and topline res", "url": "https://ca.investing.com/news/stock-market-news/phathom-pharmaceuticals-completes-enrollment-in-phase-2-eoe-study-93CH-4703117", "source_name": "Investing.com Canada", "published_at": "2026-06-23T12:20:59", "published_display": "23 Jun 2026 12:20", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phathom (PHAT) fully enrolls Phase 2 VOQUEZNA EoE trial, data in Q4 2026", "summary": "Phathom Pharmaceuticals has completed enrollment for its Phase 2 pHalcon-EoE-201 trial of VOQUEZNA (vonoprazan) for adults with eosinophilic esophagitis (EoE), enrolling 95 patients across 41 U.S. sites. Topline results are anticipated in the fourth quarter of 2026. Positive outc", "url": "https://www.stocktitan.net/sec-filings/PHAT/8-k-phathom-pharmaceuticals-inc-reports-material-event-d282324545ba.html", "source_name": "Stock Titan", "published_at": "2026-06-23T11:59:00", "published_display": "23 Jun 2026 11:59", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phathom enrolls 95 adults in VOQUEZNA EoE trial; results due in Q4", "summary": "Phathom Pharmaceuticals has completed patient enrollment ahead of schedule in its Phase 2 pHalcon-EoE-201 study for VOQUEZNA as a treatment for eosinophilic esophagitis (EoE), enrolling 95 adult patients across 41 U.S. sites. Topline results for the 12-week double-blind portion o", "url": "https://www.stocktitan.net/news/PHAT/phathom-pharmaceuticals-completes-patient-enrollment-ahead-of-il8ro36m11pf.html", "source_name": "Stock Titan", "published_at": "2026-06-23T11:58:59", "published_display": "23 Jun 2026 11:58", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA\u00ae (vonoprazan) in Eosinophilic Esophagitis (EoE)", "summary": "Phathom Pharmaceuticals has completed patient enrollment ahead of schedule for its Phase 2 pHalcon-EoE-201 clinical trial, evaluating VOQUEZNA\u00ae (vonoprazan) as a treatment for eosinophilic esophagitis (EoE) in adults. The study, which enrolled 95 patients, is the first large, pla", "url": "https://www.globenewswire.com/news-release/2026/06/23/3315866/0/en/phathom-pharmaceuticals-completes-patient-enrollment-ahead-of-schedule-in-phase-2-phalcon-eoe-201-study-of-voquezna-vonoprazan-in-eosinophilic-esophagitis-eoe.html", "source_name": "GlobeNewswire", "published_at": "2026-06-23T11:58:59", "published_display": "23 Jun 2026 11:58", "sentiment": "positive", "sentiment_pct": 68, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phathom completes enrollment in vonoprazan trial for EoE", "summary": "Phathom Pharmaceuticals Inc. announced the completion of enrollment for its Phase 2 clinical trial evaluating vonoprazan tablets for eosinophilic esophagitis (EoE), involving 95 adult patients across 41 U.S. sites. Topline results are expected in Q4 2026. The company, which has s", "url": "https://www.investing.com/news/company-news/phathom-completes-enrollment-in-vonoprazan-trial-for-eoe-93CH-4755418", "source_name": "Investing.com", "published_at": "2026-06-23T08:10:00", "published_display": "23 Jun 2026 08:10", "sentiment": "positive", "sentiment_pct": 64, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT): When Will It Breakeven?", "summary": "This article analyzes Phathom Pharmaceuticals, Inc.'s path to profitability, focusing on analyst expectations for when the company will reach breakeven. It reviews the pharmaceutical company's financial performance, including its cash burn rates and anticipated revenue growth, to", "url": "https://news.futunn.com/en/post/73798831/phathom-pharmaceuticals-inc-nasdaq-phat-when-will-it-breakeven", "source_name": "\u5bcc\u9014\u725b\u725b", "published_at": "2026-06-22T16:40:59", "published_display": "22 Jun 2026 16:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phathom Pharmaceuticals Inc (PHAT) Valuation: PE, PB & Fair Value Analysis", "summary": "Phathom Pharmaceuticals Inc (PHAT) currently has a valuation score of 8.43, placing it 94th out of 157 in the Pharmaceuticals industry. The article notes that relevant data for P/E, P/B, P/S, and P/CF ratios have not been disclosed by the company yet, suggesting a lack of compreh", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-phat/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T09:09:14", "published_display": "18 Jun 2026 09:09", "sentiment": "negative", "sentiment_pct": 42, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phathom Pharmaceuticals Inc (PHAT) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Phathom Pharmaceuticals Inc (PHAT) has a stable financial score of 8.16, ranking 74th in the Pharmaceuticals industry, indicating high operating efficiency. The company reported a significant year-over-year revenue increase of 104.43% to $58.30 million and a net profit increase o", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-phat/financial-health", "source_name": "TradingKey", "published_at": "2026-06-18T02:09:14", "published_display": "18 Jun 2026 02:09", "sentiment": "positive", "sentiment_pct": 77, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Buy on Phathom stock, $26 target", "summary": "H.C. Wainwright has reiterated a Buy rating for Phathom Pharmaceuticals (NASDAQ:PHAT) with a $26 price target, citing substantial upside from its current $10.43 stock price. The firm's positive outlook follows a webinar highlighting clinical enthusiasm for Phathom's drug VOQUEZNA", "url": "https://www.investing.com/news/analyst-ratings/hc-wainwright-reiterates-buy-on-phathom-stock-26-target-93CH-4747099", "source_name": "Investing.com", "published_at": "2026-06-17T23:10:46", "published_display": "17 Jun 2026 23:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phathom Pharmaceuticals Inc (PHAT) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides historical data on dividends and stock splits for Phathom Pharmaceuticals Inc (PHAT). It notes that PHAT has not distributed any dividends over the past five years and shows no record of stock splits. The company's current stock performance and market capita", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-phat/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T20:39:22", "published_display": "17 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phathom Pharmaceuticals Inc (PHAT) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Phathom Pharmaceuticals Inc (PHAT), outlining major shareholders, institutional holdings, and related ETF investments. Key shareholders include Frazier Life Sciences Management, L.P. and Medicxi Ventures (UK) LLP, with significant", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-phat/ownership", "source_name": "TradingKey", "published_at": "2026-06-17T19:39:22", "published_display": "17 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PHAT Reiterates by HC Wainwright & Co. -- Price Target Maintained at $26", "summary": "HC Wainwright & Co. has reiterated a \"Buy\" rating for Phathom Pharmaceuticals (PHAT), maintaining its price target at $26. Despite this positive analyst sentiment, the company's GF Score\u2122 is 27/100, reflecting low financial strength and profitability, though it shows positive mom", "url": "https://www.gurufocus.com/news/8920400/phat-reiterates-by-hc-wainwright-co-price-target-maintained-at-26", "source_name": "GuruFocus", "published_at": "2026-06-17T11:39:22", "published_display": "17 Jun 2026 11:39", "sentiment": "positive", "sentiment_pct": 63, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phathom: Why I\u2019m Downgrading To \"Sell\" Ahead Of Competition (NASDAQ:PHAT)", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxPZVJfamI1RWtqY3M2X3U4RkxaandNM2dzQXJTc3h4WjRFbWFOSEdiNmRsYnJqMkF0cmdEcVgwc3Jycmx6RENqZ1pkb0xjWk9PMGRrU3o4N3dieFQ1RldldmI1dngwX3M2ZE9jNjhMSVZOZnFyanpOeGg1Q2d2RFJNbi1NQzh4MXlqbExGRUV6N1hhVk0xdjgxMmpRTnQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PHAT - Phathom Pharmaceuticals Inc Stock Price and Quote", "summary": "This article provides comprehensive stock information for Phathom Pharmaceuticals Inc (PHAT), including its current price, market capitalization, financial metrics, and recent news. It also lists analyst ratings and insider trading activities, offering a detailed overview of the ", "url": "https://finviz.com/stock?t=PHAT", "source_name": "Finviz", "published_at": "2026-06-01T04:11:06", "published_display": "01 Jun 2026 04:11", "sentiment": "positive", "sentiment_pct": 62, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phathom Pharmaceuticals shows negative capital efficiency, destroying value amid high R&D costs.", "summary": "Phathom Pharmaceuticals currently exhibits a negative Return on Invested Capital (ROIC) of -53.45%, significantly below its Weighted Average Cost of Capital (WACC) of 15.49%, indicating it is destroying shareholder value. This is typical for clinical-stage biopharmaceutical compa", "url": "https://pluang.com/en/news-feed/analisis-efisiensi-modal-phathom-pharma", "source_name": "Pluang", "published_at": "2026-05-28T20:40:11", "published_display": "28 May 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] Phathom Pharmaceuticals, Inc. Insider Trading Activity", "summary": "Phathom Pharmaceuticals director Asit Parikh reported gifting 56,000 shares of common stock on May 22, 2026. These transfers were bona fide gifts to a trust benefiting his spouse and were not market trades. The transactions reflect estate or family planning rather than buying or ", "url": "https://www.stocktitan.net/sec-filings/PHAT/form-4-phathom-pharmaceuticals-inc-insider-trading-activity-b53a66aac4ff.html", "source_name": "Stock Titan", "published_at": "2026-05-27T20:10:17", "published_display": "27 May 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How (PHAT) Movements Inform Risk Allocation Models", "summary": "This article analyzes Phathom Pharmaceuticals Inc. (NASDAQ: PHAT) using AI models, highlighting weak near-term sentiment but potential long-term strength. It outlines various trading strategies\u2014position, momentum, and risk hedging\u2014and provides multi-timeframe signal analysis with", "url": "https://news.stocktradersdaily.com/news_release/1/How_PHAT_Movements_Inform_Risk_Allocation_Models_052626043402_1779784442.html", "source_name": "Stock Traders Daily", "published_at": "2026-05-26T04:34:00", "published_display": "26 May 2026 04:34", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PHAT SEC Filings - Phathom Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms", "summary": "This page provides a comprehensive overview of Phathom Pharmaceuticals (PHAT) SEC filings, including annual 10-K reports, quarterly 10-Q earnings, and 8-K material event disclosures. It details recent insider transactions, changes in beneficial ownership by various investment gro", "url": "https://www.stocktitan.net/sec-filings/PHAT/page-5.html", "source_name": "Stock Titan", "published_at": "2026-05-24T13:09:26", "published_display": "24 May 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/phathom-pharmaceuticals-participate-upcoming-investor-120000299.html", "source_name": "GlobeNewswire", "published_at": "2026-05-22T12:00:00+00:00", "published_display": "22 May 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual Meeting", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/phathom-pharmaceuticals-highlights-breadth-independent-120000522.html", "source_name": "GlobeNewswire", "published_at": "2026-05-20T12:00:00+00:00", "published_display": "20 May 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phathom Pharmaceuticals Highlights Breadth of Independent", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwJBVV95cUxQSnJGRDF1VXVpTzJVUHJqeUlleG13b0dYVUZhelhGVEJOTVFONkRhWm5yaGRJV3BJbFlsVUFFR1lqcHhEWjU0UV9McUR5TGdkZDVRTlpJeEZ2QVJNZTluV2lneGYtdTFyVUotR283eDFMTFh0T2JnRXpET2JJdFdVdmtiYndsOTU1M0dhUjdxZllQakhPLXVvOUluOXp0cHJGNkpFQ0o0eVRtVFZTRjJOR3JYNnczU1o4Z1RaamNiRUVySDBXRjRMX0pfenFjOHhxZEgwS0Z2ekFQRTZxaTF6ZXQ5ejFxQU1VNFBuQlptNW5Bd1JHdHh3YzRyQVRnWWJLdDlNQjdGWHZWMGpvRGg3UjJwUHBoenRaVjFVblVjNA?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Phathom (PHAT) Is Up 9.4% After Reaffirming 2026 Profitability Timeline And Narrowing Q1 Loss", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-09T07:00:00+00:00", "published_display": "09 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Phathom Pharmaceuticals (PHAT) Valuation After Narrower Losses And Reaffirmed Profitability Timeline", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phathom Pharmaceuticals (PHAT) Is Up 11.0% After Narrowing Q1 Loss And Reaffirming 2026 Profitability Timeline", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxQaXhDR0VSYUJJUTQzTHZUZ1E3ZlNvMnJWcl84SlBFN2JPVS1xMDlPelpfMktmejgyclFWNVNaZmx3ZmxyWlR4enFKdmRvaUJKZ01NSUR6MFcyN2RoR08xMmVPblNUdEgtWklKMFBpaHV5cVZfQUlWcFloeVUwcFhCY2NaZlJpTmgybzNYOHRjZXdQLXQtelBQeGdick9KWjg?oc=5", "source_name": "Market source", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Phathom Pharmaceuticals (PHAT) Narrative Is Shifting Around Profitability And Exclusivity Risks", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQWUFfVkhWZks1SEw5VWJxNC1xdV8zNl9VZDIwOWpNTzBpZURwcHNXNFJsOEVYaTNhT3JfNHRkREFFTlBJa2tRWWJ6akx1ZzNzOXIycGRKb3BuLXVZSHZhUGI0ZGdZWTJ0QXJTUXVoUmctU2o3Nkp6RDJSX2ItUHo4eHVHTllfWlFmemNwNWNBbThyZ2dYeGRCUFVaNFJvcFFBT3Y1WEVhRlhYaE5NSFI0TkVn?oc=5", "source_name": "Market source", "published_at": "2026-05-03T07:00:00+00:00", "published_display": "03 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phathom Pharmaceuticals to Highlight VOQUEZNA\u00ae (vonoprazan) at DDW 2026 Annual Meeting", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/phathom-pharmaceuticals-highlight-voquezna-vonoprazan-120000835.html", "source_name": "GlobeNewswire", "published_at": "2026-05-01T12:00:00+00:00", "published_display": "01 May 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phathom Pharmaceuticals Q1 Earnings Call Highlights", "summary": "", "url": "https://finance.yahoo.com/m/016b401d-33bd-3cc8-845e-53db70ecb21e/phathom-pharmaceuticals-q1.html", "source_name": "MarketBeat", "published_at": "2026-05-01T01:41:05+00:00", "published_display": "01 May 2026 01:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phathom Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary", "summary": "", "url": "https://finance.yahoo.com/m/2551a383-ab88-37b8-9a53-70892b115960/phathom-pharmaceuticals%2C-inc..html", "source_name": "Moby", "published_at": "2026-05-01T00:48:51+00:00", "published_display": "01 May 2026 00:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phathom (PHAT) Q1 2026 Earnings Transcript", "summary": "", "url": "https://finance.yahoo.com/m/079929f2-6ab2-398e-9a8d-c1ae9baef2f2/phathom-%28phat%29-q1-2026.html", "source_name": "Motley Fool", "published_at": "2026-04-30T21:16:13+00:00", "published_display": "30 Apr 2026 21:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings call transcript: Phathom Pharmaceuticals beats EPS expectations in Q1 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxOQldRb20wVnU4SENkVVNMaF9pSjNXanJGS0oyaUs0N1BfUzJ1a0ZRTDB6eVY3bHB4ZW9mRGJzaEF5OHRnSW5QcTlWVDRIZTR0eFJ3M25HbHZjb3dvQng5N2VHLWp6MFVIV2EteFFaUlFNdXJmdld0QVRFOWJORzRVT1gwWDZDanJuXzlDZEUzVHBySG5MNDNJZWtFckNsb0VxTmp5dE9OWEJWTGhoUVNhaEhFY2pVck1HNGpiY1dKdm5MSDgweWFjU1FRRHJINW55d2ZfYQ?oc=5", "source_name": "Investing.com", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "1.35M VOQUEZNA prescriptions filled; Phathom expects Q3 operating profitability", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQSm54SnBBV0xpbnpaTmhLQmM3Z052aHRoT2ZaNjlsRUVCRXEtSUp0Zzh1LUlGNGh1RVR5NHdSZnVLWUp4bWFIVFhWOGlYOTZpY0RVNFkxZnVWT3k5N1lDOEhJd2hVdHhqbWJRc2xxTm5FQ0xwcl9EUWFOOUpKVzdYX0VQZXMzRmhwYXJiak15QnVXVS1lZmRmVkUtblB4R3NMWEZtZE91Q0JTZ2JtNmFib2t2enBSWDJId05jOEl4blc?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi_gFBVV95cUxQWW5ackFUN3VCOWRMOUt5OGVvRG1PQ01XVzhQdDZRb3NuMms4T1NrWHBKSlQxdHVOeE1zc0JXX0V6THhSZWN3aFhSR2MxZXVPRUxDTUVNWlJpYlFsTFFnQ3U0UUdOM1BSQnlaNE9Cc2xsdVVrc05kRTdZY25NNzAwM2NoejZvN252dXZIMm0zZ0tNYWlMVF9RZXhvTEs5WGE2UWZmemtBNFN2WnFQQ0VYMUw2M0JTQ2F0NUxHRGkzSlM4UzYwVDV4LWtadHRBSFNjUTduVlBUbTRvb0NiVnp3Ui15M28zcC1JNDl2ZzJUQ3M3S2o5X2JiZkJkLW5fQQ?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Tops Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNSW4wTWYtS1FiamYxS1RLYVpONU44cE0yMXdiQ2hlaG56MWVuYWJRRS0xMlZYN1FOZ0FDTjFPZUlFdFBMRF9POHk2aXlIY2d6eTlUMFhmR3N2XzBfNGJTNVZYTFcwcDI1anZBbHVQOVBqR282SDNTbmdacEJKTTJpNXlfOWozaG1hMDBiQzJDMzYtV3dIM1Q1VlJpRXJRdGlwTEV0MUEtNmdOb2xraHc?oc=5", "source_name": "Market source", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phathom Pharmaceuticals (PHAT) Loss Compression Challenges Bearish Narratives After Q1 2026 Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Phathom Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, April 30, 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxQcHdkdE5JWkNVaEs3ZDJVb3pWb0N6ZzZ0SnJkaURsZHgxLUR6NTNhMElBb0wzVDFYQ0lGY3hTTFlCemNSREVVNFk3N3lNNGpqTy1XcW1SQ1VwRWdMZThyc01FZm45SnRrTlZqWDlLbEhpelU0RThjSFNsemNnZHJQM3pTTGJZdkpwb3FuVTYzY25CM2xzWnEyTWhsNURqZ3dyazBHaTlsZ0tUb01GNndoQ1Uzdw?oc=5", "source_name": "Market source", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Phathom Pharmaceuticals (PHAT) Valuation After Strong One Year Shareholder Return", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxOWHBuVmRKTVNWalZfLS1uemxyNHpDdk1XbE16cXUwWVgtNl9nSWxRc1NkZDNBbTA3NklmMW1vWDlaS01zUlduSjRkY0VOcUo1eVQ3QW9rUWdxcE84TjlPeUNHMHNNWUp5WDktblpwNlhrTkFSTll5d0s2VkFrajFQZTRWRERjUDlSVXhCb3hUeUpwaDN0QlVpOXZRVU5pakRlb1BCaFdGQkp1cWY2VktHcVhONA?oc=5", "source_name": "Market source", "published_at": "2026-04-16T07:00:00+00:00", "published_display": "16 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Form 4 Phathom Pharmaceuticals Inc For: 16 July By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxOd0QyTWhzZy1JenVHdkpsT3JwSlBnZ3dLRHRvOXV0WEt3bHJsdkpyNkFzVHJYV2NMYmlaVEdZVG9Fejg4eDJIeVN0UEJtRXpLb05TcTdOa2FJVXo5Z3RkemtKaDJIS1I0MGRaTmpmWHJReVVBcUFoQXJUQ0ZVVm1EeUhDY04zcXVkYjdjMmdaM0lBdXAtbGw4U3VvM2wxTlhiem1HbndsT0lrYmc?oc=5", "source_name": "Investing.com Nigeria", "published_at": "2026-07-16T21:21:39+00:00", "published_display": "16 Jul 2026 21:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phathom Pharmaceuticals (PHAT) officer surrenders 1,555 for tax withholding", "summary": "Robert Charles Breedlove, Principal Accounting Officer of Phathom Pharmaceuticals, Inc., surrendered 1,555 shares of common stock at $11.035 per share on July 14, 2026, to satisfy tax withholding obligations related to restricted stock units. This F-code disposition means shares ", "url": "https://www.stocktitan.net/sec-filings/PHAT/form-4-phathom-pharmaceuticals-inc-insider-trading-activity-b3052072f91f.html", "source_name": "Stock Titan", "published_at": "2026-07-16T20:41:21", "published_display": "16 Jul 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phathom Pharmaceuticals Inc (PHAT) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Phathom Pharmaceuticals Inc (PHAT), detailing its current price momentum score, support and resistance levels, and indicator readings. The analysis covers various technical indicators like MACD, RSI, and moving averages, concluding wi", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-phat/technical", "source_name": "TradingKey", "published_at": "2026-07-13T21:11:57", "published_display": "13 Jul 2026 21:11", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phathom Pharmaceuticals (PHAT) Short Interest & Short Float | Updated Jul 2026 $PHAT", "summary": "As of June 30, 2026, Phathom Pharmaceuticals (PHAT) had 11.99 million shares sold short, marking a 7.44% increase from the prior report and representing 16.59% of the public float. The short interest ratio is 11.7 days to cover, indicating strong pessimism about the stock. The ar", "url": "https://www.marketbeat.com/stocks/NASDAQ/PHAT/short-interest/", "source_name": "MarketBeat", "published_at": "2026-07-10T21:11:57", "published_display": "10 Jul 2026 21:11", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avoiding Lag: Real-Time Signals in (PHAT) Movement", "summary": "Phathom Pharmaceuticals Inc. (NASDAQ: PHAT) is showing strong near and mid-term sentiment, potentially extending to a long-term uptrend, although it is currently testing resistance. AI models suggest specific trading strategies, including a long position with a target of $12.31 a", "url": "https://news.stocktradersdaily.com/news_release/132/Avoiding_Lag:_Real-Time_Signals_in_PHAT_Movement_070926093202_1783603922.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-09T09:46:05", "published_display": "09 Jul 2026 09:46", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Phathom Pharmaceuticals, Inc. \u2013 NASDAQ:PHAT", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNVGxUczdZME5FUEt6NHJGbFp3bVRMN1RyX1Q5QVlvN3MzNmR0RGxBdXFxZ3A3V19oWl9uMU1iRHQ2LV9Mc2dYTGVOZFRiOW1SRGo0RDlaQXBkTlFhM2ZfNXFZV19QTkkzQm54UjVmMF9mVWhLUktZR0xBZTJQcWdPZHR6ZlFKQi1Vd0J6WGhQVGxmd1NYczc4MjlUbFpOOHJnSEQ2SzAzLXFuTURPOEE?oc=5", "source_name": "TradingView", "published_at": "2026-07-06T09:45:27+00:00", "published_display": "06 Jul 2026 09:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Phathom Pharmaceuticals, Inc. \u2013 NASDAQ:PHAT", "summary": "This article displays the \"Price to book forward\" metric for Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) on the TradingView platform. It provides financial data and indicates that the market was closed at the time the information was presented. The content primarily lists naviga", "url": "https://www.tradingview.com/symbols/NASDAQ-PHAT/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T09:41:36", "published_display": "06 Jul 2026 09:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Phathom Pharmaceuticals, Inc. \u2013 NASDAQ:PHAT", "summary": "This article briefly mentions the \"Price to sales forward\" metric for Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT). It appears to be a financial data point from TradingView, indicating a value change for the company. The rest of the content consists of navigation links and copyri", "url": "https://www.tradingview.com/symbols/NASDAQ-PHAT/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T08:42:41", "published_display": "06 Jul 2026 08:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PHAT - Phathom Pharmaceuticals Inc Revenue Breakdown", "summary": "This article provides a detailed financial breakdown for Phathom Pharmaceuticals Inc (PHAT), including its last closing price, market capitalization, income, sales, and various financial ratios. It also lists key performance indicators, stock ownership details, and price performa", "url": "https://finviz.com/stock?t=PHAT&ta=1&p=d&ty=rv", "source_name": "Finviz", "published_at": "2026-07-01T14:40:34", "published_display": "01 Jul 2026 14:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Discipline and Rules-Based Execution in PHAT Response", "summary": "This article analyzes Phathom Pharmaceuticals Inc. (NASDAQ: PHAT), noting conflicting sentiment and a mid-channel oscillation pattern. It highlights an exceptional risk-reward setup targeting a 29.0% gain against a 0.3% risk, with specific entry, target, and stop-loss points for ", "url": "https://news.stocktradersdaily.com/news_release/139/Discipline_and_Rules-Based_Execution_in_PHAT_Response_062826082402_1782649442.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-28T08:24:00", "published_display": "28 Jun 2026 08:24", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phathom Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:PHAT)", "summary": "This article provides financial data and analyst estimates for Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT). It covers details like current stock price, historical highs and lows, market capitalization, volatility, and upcoming earnings reports. The content also addresses frequent", "url": "https://www.tradingview.com/symbols/NASDAQ-PHAT/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T05:10:25", "published_display": "26 Jun 2026 05:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PHAT Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Phathom Pharmaceuticals, Inc. (PHAT) stock, including analyst price targets and future predictions for 2027. It details the company's recent stock performance, financial metrics like revenue and earnings, and upcoming events such as the next e", "url": "https://www.tradingview.com/symbols/NASDAQ-PHAT/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T16:10:46", "published_display": "25 Jun 2026 16:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Craig-Hallum Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating", "summary": "Craig-Hallum has reiterated its Buy rating on Phathom Pharmaceuticals (PHAT.US). This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.", "url": "https://www.moomoo.com/news/post/71987765/craig-hallum-maintains-phathom-pharmaceuticals-phatus-with-buy-rating", "source_name": "Moomoo", "published_at": "2026-06-25T13:40:46", "published_display": "25 Jun 2026 13:40", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phathom Pharmaceuticals details new Voquezna launch pace, shares track gastro health focus", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxQeFVxdWN6WUpOc09La2ZFbklSQlVfY3M0ajBDODRXalRybVJnZzUtN0VVOWtpTGZaaVZZNDg2c1VEY1dlSTZiYTZiS0FqMFQ4cUtUOHdVM1JjMVJ5Qkk5anQzSk1odHlmOGpGQ01FZ2hJQXdSZmJKU3NhZTBaYzBMWWlYaEczMks3bWdlZDY4SVowUDVGZ1JyaGZiX0M4OXo0Vkh4a2oxNlFwQk9kTmZpZU1KamZ4VHNaR2hBaDlDM3ZTYUVKSEJv?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-06-25T12:07:03+00:00", "published_display": "25 Jun 2026 12:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phathom Pharmaceuticals completes enrollment in Phase 2 EoE study", "summary": "Phathom Pharmaceuticals has announced the completion of enrollment for its Phase 2 pHalcon-EoE-201 clinical trial, which is evaluating VOQUEZNA (vonoprazan) tablets for the treatment of eosinophilic esophagitis (EoE) in adults. The study enrolled 95 patients across 41 sites in th", "url": "https://www.investing.com/news/sec-filings/phathom-pharmaceuticals-completes-enrollment-in-phase-2-eoe-study-93CH-4755433", "source_name": "Investing.com", "published_at": "2026-06-23T14:10:46", "published_display": "23 Jun 2026 14:10", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phathom Pharmaceuticals Completes Patient Enrollment for Phase 2 Trial of Voquezna", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/phathom-pharmaceuticals-completes-patient-enrollment-122645393.html", "source_name": "MT Newswires", "published_at": "2026-06-23T12:26:45+00:00", "published_display": "23 Jun 2026 12:26", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phathom Pharmaceuticals completes enrollment in Phase 2 EoE study By Investing.com", "summary": "Phathom Pharmaceuticals, Inc. has announced the completion of enrollment for its Phase 2 pHalcon-EoE-201 clinical trial, which is evaluating VOQUEZNA (vonoprazan) tablets for the treatment of eosinophilic esophagitis (EoE) in adults. The trial enrolled 95 patients and topline res", "url": "https://ca.investing.com/news/stock-market-news/phathom-pharmaceuticals-completes-enrollment-in-phase-2-eoe-study-93CH-4703117", "source_name": "Investing.com Canada", "published_at": "2026-06-23T12:20:59", "published_display": "23 Jun 2026 12:20", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phathom (PHAT) fully enrolls Phase 2 VOQUEZNA EoE trial, data in Q4 2026", "summary": "Phathom Pharmaceuticals has completed enrollment for its Phase 2 pHalcon-EoE-201 trial of VOQUEZNA (vonoprazan) for adults with eosinophilic esophagitis (EoE), enrolling 95 patients across 41 U.S. sites. Topline results are anticipated in the fourth quarter of 2026. Positive outc", "url": "https://www.stocktitan.net/sec-filings/PHAT/8-k-phathom-pharmaceuticals-inc-reports-material-event-d282324545ba.html", "source_name": "Stock Titan", "published_at": "2026-06-23T11:59:00", "published_display": "23 Jun 2026 11:59", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phathom enrolls 95 adults in VOQUEZNA EoE trial; results due in Q4", "summary": "Phathom Pharmaceuticals has completed patient enrollment ahead of schedule in its Phase 2 pHalcon-EoE-201 study for VOQUEZNA as a treatment for eosinophilic esophagitis (EoE), enrolling 95 adult patients across 41 U.S. sites. Topline results for the 12-week double-blind portion o", "url": "https://www.stocktitan.net/news/PHAT/phathom-pharmaceuticals-completes-patient-enrollment-ahead-of-il8ro36m11pf.html", "source_name": "Stock Titan", "published_at": "2026-06-23T11:58:59", "published_display": "23 Jun 2026 11:58", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA\u00ae (vonoprazan) in Eosinophilic Esophagitis (EoE)", "summary": "Phathom Pharmaceuticals has completed patient enrollment ahead of schedule for its Phase 2 pHalcon-EoE-201 clinical trial, evaluating VOQUEZNA\u00ae (vonoprazan) as a treatment for eosinophilic esophagitis (EoE) in adults. The study, which enrolled 95 patients, is the first large, pla", "url": "https://www.globenewswire.com/news-release/2026/06/23/3315866/0/en/phathom-pharmaceuticals-completes-patient-enrollment-ahead-of-schedule-in-phase-2-phalcon-eoe-201-study-of-voquezna-vonoprazan-in-eosinophilic-esophagitis-eoe.html", "source_name": "GlobeNewswire", "published_at": "2026-06-23T11:58:59", "published_display": "23 Jun 2026 11:58", "sentiment": "positive", "sentiment_pct": 68, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phathom completes enrollment in vonoprazan trial for EoE", "summary": "Phathom Pharmaceuticals Inc. announced the completion of enrollment for its Phase 2 clinical trial evaluating vonoprazan tablets for eosinophilic esophagitis (EoE), involving 95 adult patients across 41 U.S. sites. Topline results are expected in Q4 2026. The company, which has s", "url": "https://www.investing.com/news/company-news/phathom-completes-enrollment-in-vonoprazan-trial-for-eoe-93CH-4755418", "source_name": "Investing.com", "published_at": "2026-06-23T08:10:00", "published_display": "23 Jun 2026 08:10", "sentiment": "positive", "sentiment_pct": 64, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT): When Will It Breakeven?", "summary": "This article analyzes Phathom Pharmaceuticals, Inc.'s path to profitability, focusing on analyst expectations for when the company will reach breakeven. It reviews the pharmaceutical company's financial performance, including its cash burn rates and anticipated revenue growth, to", "url": "https://news.futunn.com/en/post/73798831/phathom-pharmaceuticals-inc-nasdaq-phat-when-will-it-breakeven", "source_name": "\u5bcc\u9014\u725b\u725b", "published_at": "2026-06-22T16:40:59", "published_display": "22 Jun 2026 16:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phathom Pharmaceuticals Inc (PHAT) Valuation: PE, PB & Fair Value Analysis", "summary": "Phathom Pharmaceuticals Inc (PHAT) currently has a valuation score of 8.43, placing it 94th out of 157 in the Pharmaceuticals industry. The article notes that relevant data for P/E, P/B, P/S, and P/CF ratios have not been disclosed by the company yet, suggesting a lack of compreh", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-phat/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T09:09:14", "published_display": "18 Jun 2026 09:09", "sentiment": "negative", "sentiment_pct": 42, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phathom Pharmaceuticals Inc (PHAT) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Phathom Pharmaceuticals Inc (PHAT) has a stable financial score of 8.16, ranking 74th in the Pharmaceuticals industry, indicating high operating efficiency. The company reported a significant year-over-year revenue increase of 104.43% to $58.30 million and a net profit increase o", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-phat/financial-health", "source_name": "TradingKey", "published_at": "2026-06-18T02:09:14", "published_display": "18 Jun 2026 02:09", "sentiment": "positive", "sentiment_pct": 77, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Buy on Phathom stock, $26 target", "summary": "H.C. Wainwright has reiterated a Buy rating for Phathom Pharmaceuticals (NASDAQ:PHAT) with a $26 price target, citing substantial upside from its current $10.43 stock price. The firm's positive outlook follows a webinar highlighting clinical enthusiasm for Phathom's drug VOQUEZNA", "url": "https://www.investing.com/news/analyst-ratings/hc-wainwright-reiterates-buy-on-phathom-stock-26-target-93CH-4747099", "source_name": "Investing.com", "published_at": "2026-06-17T23:10:46", "published_display": "17 Jun 2026 23:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phathom Pharmaceuticals Inc (PHAT) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides historical data on dividends and stock splits for Phathom Pharmaceuticals Inc (PHAT). It notes that PHAT has not distributed any dividends over the past five years and shows no record of stock splits. The company's current stock performance and market capita", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-phat/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T20:39:22", "published_display": "17 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phathom Pharmaceuticals Inc (PHAT) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Phathom Pharmaceuticals Inc (PHAT), outlining major shareholders, institutional holdings, and related ETF investments. Key shareholders include Frazier Life Sciences Management, L.P. and Medicxi Ventures (UK) LLP, with significant", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-phat/ownership", "source_name": "TradingKey", "published_at": "2026-06-17T19:39:22", "published_display": "17 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PHAT Reiterates by HC Wainwright & Co. -- Price Target Maintained at $26", "summary": "HC Wainwright & Co. has reiterated a \"Buy\" rating for Phathom Pharmaceuticals (PHAT), maintaining its price target at $26. Despite this positive analyst sentiment, the company's GF Score\u2122 is 27/100, reflecting low financial strength and profitability, though it shows positive mom", "url": "https://www.gurufocus.com/news/8920400/phat-reiterates-by-hc-wainwright-co-price-target-maintained-at-26", "source_name": "GuruFocus", "published_at": "2026-06-17T11:39:22", "published_display": "17 Jun 2026 11:39", "sentiment": "positive", "sentiment_pct": 63, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phathom: Why I\u2019m Downgrading To \"Sell\" Ahead Of Competition (NASDAQ:PHAT)", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxPZVJfamI1RWtqY3M2X3U4RkxaandNM2dzQXJTc3h4WjRFbWFOSEdiNmRsYnJqMkF0cmdEcVgwc3Jycmx6RENqZ1pkb0xjWk9PMGRrU3o4N3dieFQ1RldldmI1dngwX3M2ZE9jNjhMSVZOZnFyanpOeGg1Q2d2RFJNbi1NQzh4MXlqbExGRUV6N1hhVk0xdjgxMmpRTnQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PHAT - Phathom Pharmaceuticals Inc Stock Price and Quote", "summary": "This article provides comprehensive stock information for Phathom Pharmaceuticals Inc (PHAT), including its current price, market capitalization, financial metrics, and recent news. It also lists analyst ratings and insider trading activities, offering a detailed overview of the ", "url": "https://finviz.com/stock?t=PHAT", "source_name": "Finviz", "published_at": "2026-06-01T04:11:06", "published_display": "01 Jun 2026 04:11", "sentiment": "positive", "sentiment_pct": 62, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phathom Pharmaceuticals shows negative capital efficiency, destroying value amid high R&D costs.", "summary": "Phathom Pharmaceuticals currently exhibits a negative Return on Invested Capital (ROIC) of -53.45%, significantly below its Weighted Average Cost of Capital (WACC) of 15.49%, indicating it is destroying shareholder value. This is typical for clinical-stage biopharmaceutical compa", "url": "https://pluang.com/en/news-feed/analisis-efisiensi-modal-phathom-pharma", "source_name": "Pluang", "published_at": "2026-05-28T20:40:11", "published_display": "28 May 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] Phathom Pharmaceuticals, Inc. Insider Trading Activity", "summary": "Phathom Pharmaceuticals director Asit Parikh reported gifting 56,000 shares of common stock on May 22, 2026. These transfers were bona fide gifts to a trust benefiting his spouse and were not market trades. The transactions reflect estate or family planning rather than buying or ", "url": "https://www.stocktitan.net/sec-filings/PHAT/form-4-phathom-pharmaceuticals-inc-insider-trading-activity-b53a66aac4ff.html", "source_name": "Stock Titan", "published_at": "2026-05-27T20:10:17", "published_display": "27 May 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How (PHAT) Movements Inform Risk Allocation Models", "summary": "This article analyzes Phathom Pharmaceuticals Inc. (NASDAQ: PHAT) using AI models, highlighting weak near-term sentiment but potential long-term strength. It outlines various trading strategies\u2014position, momentum, and risk hedging\u2014and provides multi-timeframe signal analysis with", "url": "https://news.stocktradersdaily.com/news_release/1/How_PHAT_Movements_Inform_Risk_Allocation_Models_052626043402_1779784442.html", "source_name": "Stock Traders Daily", "published_at": "2026-05-26T04:34:00", "published_display": "26 May 2026 04:34", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PHAT SEC Filings - Phathom Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms", "summary": "This page provides a comprehensive overview of Phathom Pharmaceuticals (PHAT) SEC filings, including annual 10-K reports, quarterly 10-Q earnings, and 8-K material event disclosures. It details recent insider transactions, changes in beneficial ownership by various investment gro", "url": "https://www.stocktitan.net/sec-filings/PHAT/page-5.html", "source_name": "Stock Titan", "published_at": "2026-05-24T13:09:26", "published_display": "24 May 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/phathom-pharmaceuticals-participate-upcoming-investor-120000299.html", "source_name": "GlobeNewswire", "published_at": "2026-05-22T12:00:00+00:00", "published_display": "22 May 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual Meeting", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/phathom-pharmaceuticals-highlights-breadth-independent-120000522.html", "source_name": "GlobeNewswire", "published_at": "2026-05-20T12:00:00+00:00", "published_display": "20 May 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phathom Pharmaceuticals Highlights Breadth of Independent", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwJBVV95cUxQSnJGRDF1VXVpTzJVUHJqeUlleG13b0dYVUZhelhGVEJOTVFONkRhWm5yaGRJV3BJbFlsVUFFR1lqcHhEWjU0UV9McUR5TGdkZDVRTlpJeEZ2QVJNZTluV2lneGYtdTFyVUotR283eDFMTFh0T2JnRXpET2JJdFdVdmtiYndsOTU1M0dhUjdxZllQakhPLXVvOUluOXp0cHJGNkpFQ0o0eVRtVFZTRjJOR3JYNnczU1o4Z1RaamNiRUVySDBXRjRMX0pfenFjOHhxZEgwS0Z2ekFQRTZxaTF6ZXQ5ejFxQU1VNFBuQlptNW5Bd1JHdHh3YzRyQVRnWWJLdDlNQjdGWHZWMGpvRGg3UjJwUHBoenRaVjFVblVjNA?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phathom (PHAT) Is Up 9.4% After Reaffirming 2026 Profitability Timeline And Narrowing Q1 Loss", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-09T07:00:00+00:00", "published_display": "09 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Phathom Pharmaceuticals (PHAT) Valuation After Narrower Losses And Reaffirmed Profitability Timeline", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phathom Pharmaceuticals (PHAT) Is Up 11.0% After Narrowing Q1 Loss And Reaffirming 2026 Profitability Timeline", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxQaXhDR0VSYUJJUTQzTHZUZ1E3ZlNvMnJWcl84SlBFN2JPVS1xMDlPelpfMktmejgyclFWNVNaZmx3ZmxyWlR4enFKdmRvaUJKZ01NSUR6MFcyN2RoR08xMmVPblNUdEgtWklKMFBpaHV5cVZfQUlWcFloeVUwcFhCY2NaZlJpTmgybzNYOHRjZXdQLXQtelBQeGdick9KWjg?oc=5", "source_name": "Market source", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Phathom Pharmaceuticals (PHAT) Narrative Is Shifting Around Profitability And Exclusivity Risks", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQWUFfVkhWZks1SEw5VWJxNC1xdV8zNl9VZDIwOWpNTzBpZURwcHNXNFJsOEVYaTNhT3JfNHRkREFFTlBJa2tRWWJ6akx1ZzNzOXIycGRKb3BuLXVZSHZhUGI0ZGdZWTJ0QXJTUXVoUmctU2o3Nkp6RDJSX2ItUHo4eHVHTllfWlFmemNwNWNBbThyZ2dYeGRCUFVaNFJvcFFBT3Y1WEVhRlhYaE5NSFI0TkVn?oc=5", "source_name": "Market source", "published_at": "2026-05-03T07:00:00+00:00", "published_display": "03 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phathom Pharmaceuticals to Highlight VOQUEZNA\u00ae (vonoprazan) at DDW 2026 Annual Meeting", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/phathom-pharmaceuticals-highlight-voquezna-vonoprazan-120000835.html", "source_name": "GlobeNewswire", "published_at": "2026-05-01T12:00:00+00:00", "published_display": "01 May 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phathom Pharmaceuticals Q1 Earnings Call Highlights", "summary": "", "url": "https://finance.yahoo.com/m/016b401d-33bd-3cc8-845e-53db70ecb21e/phathom-pharmaceuticals-q1.html", "source_name": "MarketBeat", "published_at": "2026-05-01T01:41:05+00:00", "published_display": "01 May 2026 01:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phathom Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary", "summary": "", "url": "https://finance.yahoo.com/m/2551a383-ab88-37b8-9a53-70892b115960/phathom-pharmaceuticals%2C-inc..html", "source_name": "Moby", "published_at": "2026-05-01T00:48:51+00:00", "published_display": "01 May 2026 00:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phathom (PHAT) Q1 2026 Earnings Transcript", "summary": "", "url": "https://finance.yahoo.com/m/079929f2-6ab2-398e-9a8d-c1ae9baef2f2/phathom-%28phat%29-q1-2026.html", "source_name": "Motley Fool", "published_at": "2026-04-30T21:16:13+00:00", "published_display": "30 Apr 2026 21:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings call transcript: Phathom Pharmaceuticals beats EPS expectations in Q1 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxOQldRb20wVnU4SENkVVNMaF9pSjNXanJGS0oyaUs0N1BfUzJ1a0ZRTDB6eVY3bHB4ZW9mRGJzaEF5OHRnSW5QcTlWVDRIZTR0eFJ3M25HbHZjb3dvQng5N2VHLWp6MFVIV2EteFFaUlFNdXJmdld0QVRFOWJORzRVT1gwWDZDanJuXzlDZEUzVHBySG5MNDNJZWtFckNsb0VxTmp5dE9OWEJWTGhoUVNhaEhFY2pVck1HNGpiY1dKdm5MSDgweWFjU1FRRHJINW55d2ZfYQ?oc=5", "source_name": "Investing.com", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "1.35M VOQUEZNA prescriptions filled; Phathom expects Q3 operating profitability", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQSm54SnBBV0xpbnpaTmhLQmM3Z052aHRoT2ZaNjlsRUVCRXEtSUp0Zzh1LUlGNGh1RVR5NHdSZnVLWUp4bWFIVFhWOGlYOTZpY0RVNFkxZnVWT3k5N1lDOEhJd2hVdHhqbWJRc2xxTm5FQ0xwcl9EUWFOOUpKVzdYX0VQZXMzRmhwYXJiak15QnVXVS1lZmRmVkUtblB4R3NMWEZtZE91Q0JTZ2JtNmFib2t2enBSWDJId05jOEl4blc?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi_gFBVV95cUxQWW5ackFUN3VCOWRMOUt5OGVvRG1PQ01XVzhQdDZRb3NuMms4T1NrWHBKSlQxdHVOeE1zc0JXX0V6THhSZWN3aFhSR2MxZXVPRUxDTUVNWlJpYlFsTFFnQ3U0UUdOM1BSQnlaNE9Cc2xsdVVrc05kRTdZY25NNzAwM2NoejZvN252dXZIMm0zZ0tNYWlMVF9RZXhvTEs5WGE2UWZmemtBNFN2WnFQQ0VYMUw2M0JTQ2F0NUxHRGkzSlM4UzYwVDV4LWtadHRBSFNjUTduVlBUbTRvb0NiVnp3Ui15M28zcC1JNDl2ZzJUQ3M3S2o5X2JiZkJkLW5fQQ?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Tops Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNSW4wTWYtS1FiamYxS1RLYVpONU44cE0yMXdiQ2hlaG56MWVuYWJRRS0xMlZYN1FOZ0FDTjFPZUlFdFBMRF9POHk2aXlIY2d6eTlUMFhmR3N2XzBfNGJTNVZYTFcwcDI1anZBbHVQOVBqR282SDNTbmdacEJKTTJpNXlfOWozaG1hMDBiQzJDMzYtV3dIM1Q1VlJpRXJRdGlwTEV0MUEtNmdOb2xraHc?oc=5", "source_name": "Market source", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phathom Pharmaceuticals (PHAT) Loss Compression Challenges Bearish Narratives After Q1 2026 Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phathom Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, April 30, 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxQcHdkdE5JWkNVaEs3ZDJVb3pWb0N6ZzZ0SnJkaURsZHgxLUR6NTNhMElBb0wzVDFYQ0lGY3hTTFlCemNSREVVNFk3N3lNNGpqTy1XcW1SQ1VwRWdMZThyc01FZm45SnRrTlZqWDlLbEhpelU0RThjSFNsemNnZHJQM3pTTGJZdkpwb3FuVTYzY25CM2xzWnEyTWhsNURqZ3dyazBHaTlsZ0tUb01GNndoQ1Uzdw?oc=5", "source_name": "Market source", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Phathom Pharmaceuticals (PHAT) Valuation After Strong One Year Shareholder Return", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxOWHBuVmRKTVNWalZfLS1uemxyNHpDdk1XbE16cXUwWVgtNl9nSWxRc1NkZDNBbTA3NklmMW1vWDlaS01zUlduSjRkY0VOcUo1eVQ3QW9rUWdxcE84TjlPeUNHMHNNWUp5WDktblpwNlhrTkFSTll5d0s2VkFrajFQZTRWRERjUDlSVXhCb3hUeUpwaDN0QlVpOXZRVU5pakRlb1BCaFdGQkp1cWY2VktHcVhONA?oc=5", "source_name": "Market source", "published_at": "2026-04-16T07:00:00+00:00", "published_display": "16 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 103, "total_relevant": 72, "sentiment_summary": {"positive": 20, "negative": 13, "neutral": 39, "score": 53, "total": 72, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 79, "events": [{"event": "general", "label": "Market update", "weight": 20.7, "count": 37}, {"event": "earnings", "label": "Earnings", "weight": 13.61, "count": 27}, {"event": "analyst", "label": "Analyst action", "weight": 3.3, "count": 6}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 20, "negative_events": 13}, "market_context": {"has_market_context": true, "latest_close": 12.61, "latest_week": "2026-07-10", "one_week_move": 12.6, "four_week_move": 21.6, "twelve_week_move": -4.4, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.147494, "market_dynamics_buy_signal": false, "relative_strength": -12.2178, "fair_value_gap": 18.3, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 46.2273, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+12.6% over one week, +21.6% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 61, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 11}, {"label": "Stock Titan", "count": 6}, {"label": "GlobeNewswire", "count": 6}, {"label": "TradingKey", "count": 5}, {"label": "TradingView", "count": 5}, {"label": "simplywall.st", "count": 5}, {"label": "Investing.com", "count": 4}, {"label": "Stock Traders Daily", "count": 3}], "tiers": [{"label": "Direct company coverage", "count": 63}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 37}, {"label": "Earnings", "count": 27}, {"label": "Analyst action", "count": 6}, {"label": "Balance sheet", "count": 1}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "53/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "79/100 classification confidence."}, {"label": "Company focus", "value": "63", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+12.6% over one week, +21.6% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Form 4 Phathom Pharmaceuticals Inc For: 16 July By Investing.com"}], "updated_at": "2026-07-17T22:22:15.747658+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}